| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.65▲ | 1.65▼ | 1.65▲ | 1.65▼ | 1.72▼ |
| MA10 | 1.66▼ | 1.64▲ | 1.64▲ | 1.53▲ | 1.85▼ |
| MA20 | 1.65▲ | 1.63▲ | 1.63▲ | 1.65▼ | N/A |
| MA50 | 1.64▲ | 1.63▲ | 1.57▲ | 1.90▼ | N/A |
| MA100 | 1.71▼ | 1.52▲ | 1.61▲ | N/A | N/A |
| MA200 | 1.55▲ | 1.68▼ | 1.77▼ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.000▲ | -0.003▼ | 0.063▲ | N/A |
| RSI | 50.254▲ | 51.428▲ | 52.815▲ | 31.148▼ | N/A |
| STOCH | 39.773 | 41.061 | 45.455 | 51.473 | N/A |
| WILL %R | -54.545 | -54.545 | -31.579 | -45.714 | N/A |
| CCI | -15.514 | 52.662 | 62.012 | 38.193 | N/A |
|
Tuesday, September 08, 2026 11:33 AM
VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately.
|
|
Tuesday, September 08, 2026 09:14 AM
VERAXA Biotech (NASDAQ: VRXA) a developer of next-generation antibody-based cancer therapies, announced the appointment ...
|
|
Friday, September 04, 2026 12:00 AM
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-generation antibody-based cancer therapies, today announced the appointment of Raju Willener as Chief Financial ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/09/26 | 1.68 | 1.72 | 1.62 | 1.65 | 88,575 |
| 10/09/26 | 1.58 | 1.6822 | 1.57 | 1.65 | 400,062 |
| 09/09/26 | 1.62 | 1.65 | 1.56 | 1.59 | 188,545 |
| 08/09/26 | 1.81 | 1.90 | 1.56 | 1.60 | 468,700 |
| 04/09/26 | 1.57 | 1.97 | 1.5312 | 1.76 | 3,548,419 |
| 03/09/26 | 1.38 | 1.68 | 1.3707 | 1.53 | 559,932 |
| 02/09/26 | 1.42 | 1.435 | 1.36 | 1.38 | 176,209 |
| 01/09/26 | 1.38 | 1.5426 | 1.27 | 1.40 | 384,415 |
| 31/08/26 | 1.39 | 1.39 | 1.32 | 1.35 | 290,789 |
| 28/08/26 | 1.43 | 1.43 | 1.33 | 1.35 | 313,514 |
|
|
||||
|
|
||||
|
|